Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK plus non-small cell lung cancer (NSCLC) Meeting Abstract

Industry Collaboration

cited authors

  • Jahanzeb, M.; Lin, H. M.; Pan, X.; Yin, Y.; Hou, P.; Nordstrom, B. L.; Desai, A.; Socinski, M. A.

authors

Publication Date

  • October 1, 2018

webpage

published in

category

start page

  • 504

end page

  • 504

volume

  • 29